A highly insightful article on the commercial, regulatory, and investment landscape facing AAV gene therapy companies today. Many of the lessons are also relevant/useful for those of us pursuing distinct or adjacent gene delivery modalities. Fatma Elzahraa Eid keeps a keenly perceptive finger on the pulse of the industry. Note: this article is not all doom and gloom for gene therapy entrepreneurs; it realistically lays out the challenges while also pointing to strategies to overcome them.